Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Phenoconversion is the mismatch between the individual’s genotype-based prediction of drug metabolism and the true capacity to metabolize drugs due to nongenetic factors. While the concept of phenoconversion has been described in narrative reviews, no systematic review is available. A systematic review was conducted to investigate factors contributing to phenoconversion and the impact on cytochrome P450 metabolism. Twenty-seven studies met the inclusion criteria and were incorporated in this review, of which 14 demonstrate phenoconversion for a specific genotype group. Phenoconversion into a lower metabolizer phenotype was reported for concomitant use of CYP450-inhibiting drugs, increasing age, cancer, and inflammation. Phenoconversion into a higher metabolizer phenotype was reported for concomitant use of CYP450 inducers and smoking. Moreover, alcohol, pregnancy, and vitamin D exposure are factors where study data suggested phenoconversion. The studies reported genotype–phenotype discrepancies, but the impact of phenoconversion on the effectiveness and toxicity in the clinical setting remains unclear. In conclusion, phenoconversion is caused by both extrinsic factors and patient- and disease-related factors. The mechanism(s) behind and the extent to which CYP450 metabolism is affected remain unexplored. If studied more comprehensively, accounting for phenoconversion may help to improve our ability to predict the individual CYP450 metabolism and personalize drug treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 1×
“Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to prepare the report [19].”
MethodZanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 3×
“Inadditiontogenetics, manyotherfactors influencedrugmetabolism, suchassex, age, nutritionalcondition, hormonal and diurnal influences, concomitant drug use, or (underlying) diseases [5].”
BackgroundCPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164 · cited 4×
“For more than 100 drug–gene pairs, guidelines to manage drug treatment based on genetic test results are available from the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) [3,4].”
BackgroundMethodInfluentialPharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018 · cited 4×
“For more than 100 drug–gene pairs, guidelines to manage drug treatment based on genetic test results are available from the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) [3,4].”
BackgroundMethodInfluentialSelf-citationBirdwell, K., Decker, B., Barbarino, J., Peterson, J., Stein, C., Sadee, W., Wang, D., Vinks, A., He, Y., Swen, J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.113 · Cited by 730
Self-citationCaudle, K. E., Sangkuhl, K., Whirl‐Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., Scott, S. A., Hertz, D. L., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12692 · Cited by 536
Self-citationFormulating Questions and Locating Primary Studies for Inclusion in Systematic Reviews
Counsell, C. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-5-199709010-00008 · Cited by 505 · cited 1×
“For this systematic review, identification and selection of studies were performed according to the PICO method [18].”
MethodBORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487 · cited 2×
“In a prospective cohort study, 158 breast cancer patients were treated with tamoxifen and received concomitant treatment with CYP2D6 inhibitors [32].”
BackgroundMethodRoden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Drug interactions with smoking
Kroon, L. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060414 · Cited by 345 · cited 1×
“The interaction between smoking and CYP1A2 is well-established [47].”
BackgroundTranscriptional Control of Intestinal Cytochrome P-4503A by 1α,25-Dihydroxy Vitamin D3
Thummel, K. E., Brimer, C., Yasuda, K., Thottassery, J., Senn, T., Lin, Y., Ishizuka, H., Kharasch, E., Schuetz, J., & Schuetz, E. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1399 · Cited by 325
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.741 · Cited by 325 · cited 1×
“Vitamin D levels can induce CYP3A4 expression by binding of the vitamin D receptor complexes to proximal promotor elements [51,52].”
BackgroundAddressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Liver disease selectively modulates cytochrome P450–mediated metabolism
FRYE, R., ZGHEIB, N., MATZKE, G., CHAVESGNECCO, D., RABINOVITZ, M., SHAIKH, O., & BRANCH, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.006 · Cited by 250
Bank, P., Caudle, K., Swen, J., Gammal, R., Whirl‐Carrillo, M., Klein, T., Relling, M., & Guchelaar, H. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.762 · Cited by 238 · cited 1×
“Phenotype assignment was performed according to the latest guidelines [15,20].”
MethodSelf-citationInduction of CYP2D6 in pregnancy*
Wadelius, M., Darj, E., Frenne, G., & Rane, A. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90118-1 · Cited by 226 · cited 2×
“In a prospective study of 140 women, the effect of pregnancy on CYP2D6 activity was investigated [43].”
BackgroundPharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem
Klein, K., & Zanger, U. M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00012 · Cited by 220
Shah, R. R., & Smith, R. L. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061093 · Cited by 197
Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172 · cited 1×
“, inflammation) may only develop after prolonged or repeated exposure, which requires in-vitro models, such as 3D liver spheroids, in which the long-term consequences of these factors for drug metabolism can be adequately studied [68,69].”
BackgroundVoriconazole metabolism is influenced by severe inflammation: a prospective study
Veringa, A., ter Avest, M., Span, L. F. R., van den Heuvel, E. R., Touw, D. J., Zijlstra, J. G., Kosterink, J. G. W., van der Werf, T. S., & Alffenaar, J.-W. C. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw349 · Cited by 161 · cited 2×
“It was found that for CYP2C19 UMs, NMs, and IMs, at higher C-reactive protein (CRP) concentrations, the metabolic ratio was decreased, and, consequently, the voriconazole trough concentration was increased [40].”
BackgroundiPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery
Corbett, J. L., & Duncan, S. A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00265 · Cited by 138
Giraud, C., Tran, A., Rey, E., Vincent, J., Tréluyer, J., & Pons, G. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1279 · Cited by 123 · cited 6×
“Pharmacological Class Drug Enzyme Cause of Phenoconversion Type of Interaction Drug/Factor Responsible for Phenoconversion Type of Study Genotype Assessment Phenotype Assessment Effect of Phenoconversion Subjects Ref Anticonvulsants Valproate CYP2C19 Comedication Inhibition Stiripentol 2 CYP2C9*1/*2/*3 Concentration-t…”
BackgroundInfluentialTran, A., Rey, E., Pons, G., Rousseau, M., d'Athis, P., Olive, G., Mather, G. G., Bishop, F. E., Wurden, C. J., Labroo, R., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90044-8 · Cited by 108 · cited 9×
“Clobazam is mainly metabolized by CYP3A4 and partially by CYP2C19 and CYP2B6 into the active metabolite N-desmethyl-clobazam [46].”
BackgroundInfluentialEffect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy
Ververs, T. F., Voorbij, H. A. M., Zwarts, P., Belitser, S. V., Egberts, T. C. G., Visser, G. H. A., & Schobben, A. F. A. M. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318050-000000000-00000 · Cited by 101
Andreu, F., Colom, H., Elens, L., van Gelder, T., van Schaik, R. H. N., Hesselink, D. A., Bestard, O., Torrás, J., Cruzado, J. M., Grinyo, J. M., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0491-3 · Cited by 95
Teft, W. A., Gong, I. Y., Dingle, B., Potvin, K., Younus, J., Vandenberg, T. A., Brackstone, M., Perera, F. E., Choi, Y., Zou, G., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2511-4 · Cited by 89 · cited 1×
“In a prospective study of 196 breast cancer patients receiving tamoxifen, plasma concentrations of tamoxifen and its metabolite endoxifen were evaluated [33].”
BackgroundMeek, M. D., & Finch, G. L. (1999) · Environmental Research · doi:10.1006/enrs.1998.3872 · Cited by 87 · cited 1×
“Once activated, the aryl hydrocarbon receptor induces the expression of the CYP1A1 and CYP1A2 enzymes [48].”
BackgroundA discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
Williams, M. L., Bhargava, P., Cherrouk, I., Marshall, J. L., Flockhart, D. A., & Wainer, I. W. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00189.x · Cited by 73 · cited 2×
“In a prospective study of 16 patients with advanced cancer and a CYP2C19 NM genotype, the relationship between the CYP2C19 genotype and phenotype was studied [35].”
Background石澤, 幸., Yasui‐Furukori, N., Takahata, T., Sasaki, M., & Tateishi, T. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00005 · Cited by 71 · cited 4×
“However, based on proguanil metabolism, 27% of the genotypically predicted CYP2C19 NMs and 53% of the genotypically predicted CYP2C19 IMs were phenotypically CYP2C19 PMs. 3.4.3.”
BackgroundInfluentialLesche, D., Mostafa, S., Everall, I., Pantelis, C., & Bousman, C. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0108-y · Cited by 71 · cited 1×
“A recent study of patients treated with clozapine investigated the use of genotype- and comedication-corrected scores to predict the impact on clozapine exposure [62].”
BackgroundImpact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions
Storelli, F., Matthey, A., Lenglet, S., Thomas, A., Desmeules, J. A., & Daali, Y. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.889 · Cited by 66
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
Helsby, N. A., Lo, W.-Y., SHARPLES, K. J., Riley, G., Murray, M., Spells, K. P., Dzhelai, M., Simpson, A., & Findlay, M. P. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604699 · Cited by 65 · cited 2×
“A similar study of 33 patients with advanced cancer aimed to replicate these results [36].”
BackgroundPatteet, L., Haufroid, V., Kristof, M., Bernard, S., Morrens, M., & Neels, H. M. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1965-1 · Cited by 65 · cited 2×
“In a prospective study of 82 psychiatric patients receiving treatment with one of the CYP2D6 substrates aripiprazole, haloperidol, paliperidone, risperidone or zuclopenthixol, the concomitant use of a CYP2D6 inhibitor was investigated [26].”
BackgroundWoillard, J., Mourad, M., Neely, M. N., Capron, A., van Schaik, R. H., van Gelder, T., Lloberas, N., Hesselink, D. A., Marquet, P., Haufroid, V., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00358 · Cited by 65
Genomic Instability of iPSCs and Challenges in Their Clinical Applications
Yoshihara, M., Oguchi, A., & Murakawa, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_2 · Cited by 60
Differential Genotype Dependent Inhibition of CYP2C9 in Humans
Kumar, V., Brundage, R. C., Oetting, W. S., Leppik, I. E., & Tracy, T. S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020396 · Cited by 60 · cited 1×
“In a prospective crossover study of 22 healthy volunteers, the consequences of 7-day concomitant treatment with flurbiprofen (a CYP2C9 substrate) and fluconazole (a CYP2C9 inhibitor) was investigated [30].”
BackgroundYamamoto, Y., Takahashi, Y., Imai, K., Miyakawa, K., Nishimura, S., Kasai, R., Ikeda, H., Takayama, R., Mogami, Y., Yamaguchi, T., et al. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318283b49a · Cited by 58 · cited 5×
“However, in reality, many drugs have a complex metabolism, and patients suffer from multiple morbidities and are treated with multiple drugs simultaneously [22,61].”
BackgroundInfluentialHendriks, D. F. G., Vorrink, S. U., Smutny, T., Sim, S. C., Nordling, Å., Ullah, S., Kumondai, M., Jones, B. C., Johansson, I., Andersson, T. B., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1860 · Cited by 57 · cited 1×
“, inflammation) may only develop after prolonged or repeated exposure, which requires in-vitro models, such as 3D liver spheroids, in which the long-term consequences of these factors for drug metabolism can be adequately studied [68,69].”
BackgroundSkogh, E., Sjödin, I., Josefsson, M., & Dahl, M. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318204d9e2 · Cited by 55 · cited 2×
“[28] PM: two defective alleles (*3, *4, *5 or *6 ) 132% compared to smokers with other CYP1A2 polymorphisms and, 107% compared to nonsmokers that are homozygous carriers of CYP1A2*1F (schizophrenia or schizoaffective disorder patients)”
BackgroundDickschen, K. J. R., Willmann, S., Thelen, K., Lippert, J., Hempel, G., & Eissing, T. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00092 · Cited by 50
Brynne, Svanström, Åberg‐Wistedt, Hallén, & Bertilsson (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00051.x · Cited by 48 · cited 2×
“In a prospective study of 9 depressed patients, the influence of concomitant treatment with the CYP2D6 inhibitor fluoxetine on the oral clearance of tolterodine was investigated [25].”
BackgroundMethodOhnishi, A., MURAKAMI, S., Akizuki, S., Mochizuki, J., Echizen, H., & Takagi, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280787 · Cited by 47
CYP450 Genotype and Pharmacogenetic Association Studies: a Critical Appraisal
Shah, R. R., Gaedigk, A., LLerena, A., Eichelbaum, M. F., Stingl, J., & Smith, R. L. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.172 · Cited by 46 · cited 1×
“Phenoconversion can result from the use of concomitant medication [6,7], comorbidities [7], or other factors such as smoking [8,9].”
BackgroundAntidepressant Treatment and Altered CYP2D6 Activity
D’Empaire, I., Guico‐Pabia, C. J., & Preskorn, S. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000405363.95881.01 · Cited by 41
Getting Pharmacogenomics Into the Clinic
Abbasi, J. (2016) · JAMA · doi:10.1001/jama.2016.12103 · Cited by 41 · cited 1×
“In the last decade, pharmacogenetics-informed drug dosing has progressively moved into clinical practice for various drug–gene combinations [1,2].”
BackgroundVelenosi, T. J., Feere, D. A., Sohi, G., Hardy, D. B., & Urquhart, B. L. (2014) · The FASEB Journal · doi:10.1096/fj.14-258780 · Cited by 39 · cited 1×
“While the exact mechanism remains unknown, it is recognized that indoxyl sulfate upregulates the activity of nuclear factor κB (the most important inflammatory transcription factor), and nuclear factor κB decreases histone 4 acetylation in the CYP3A promotor, which downregulates CYP3A expression [55,56].”
BackgroundPolymorphic hydroxylation of perhexiline in vitro
Sørensen, L. B., Sørensen, R., Miners, J. O., Somogyi, A. A., Grgurinovich, N., & Birkett, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01805.x · Cited by 37
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost, K. L., Brockmöller, J., Esdorn, F., et al. (1995) · PubMed · Cited by 34
Moj, D., Britz, H., Burhenne, J., Stewart, C. F., Egerer, G., Haefeli, W. E., & Lehr, T. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3447-x · Cited by 31
Kiss, Á., Vaskó, D., Déri, M. T., Tóth, K., & Monostory, K. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.12.001 · Cited by 30 · cited 6×
“Chronic alcohol consumption was found to be a factor reducing CYP2C19 activity in 13% of subjects with overestimated CYP2C19 activity [8].”
BackgroundMethodResultInfluentialPhenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment
Rost, K. L., Brockmöller, J., Esdorn, F., & Roots, I. (1995) · Journal of Hepatology · doi:10.1016/s0168-8278(95)80005-0 · Cited by 29 · cited 1×
“Phenoconversion can result from the use of concomitant medication [6,7], comorbidities [7], or other factors such as smoking [8,9].”
BackgroundDorr, C. R., Remmel, R. P., Muthusamy, A., Fisher, J., Moriarity, B. S., Yasuda, K., Wu, B., Guan, W., Schuetz, E. G., Oetting, W. S., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.076307 · Cited by 29
Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
Kiss, Á., Menus, Á., Tóth, K., Déri, M. T., Sirok, D., Gabri, E., Belic, A., Csukly, G., Bitter, I., & Monostory, K. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0975-2 · Cited by 27
Chen, Y., Zhou, D., Tang, W., Zhou, W., Al-Huniti, N. H., & Masson, E. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1036 · Cited by 25
Yamamoto, Y., Takahashi, Y., Imai, K., Mogami, Y., Matsuda, K., Nakai, M., Kagawa, Y., & Inoue, Y. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.03.018 · Cited by 25
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
Doki, K., Sekiguchi, Y., Kuga, K., Aonuma, K., & Homma, M. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.04.001 · Cited by 24
Jogamoto, T., Yamamoto, Y., Fukuda, M., Suzuki, Y., Imai, K., Takahashi, Y., Inoue, Y., & Ohtsuka, Y. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.12.014 · Cited by 24 · cited 2×
“[21] CYP2C19*1/*2/*3 PM: Valproate serum concentration ↑ (Dravet syndrome patients)”
BackgroundBurns, K. E., Goldthorpe, M. A., Porteus, F., Browett, P., & Helsby, N. A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2409-9 · Cited by 20 · cited 2×
“A prospective study of 25 multiple myeloma patients compared the occurrence of phenoconversion in hematological malignancies and solid tumors [37].”
BackgroundShiono, M., Akiyama, K., Sezai, A., Wakui, S., Kimura, H., Sekino, H., & Hata, M. (2014) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0034-1383814 · Cited by 18
Okubo, M., Murayama, N., Miura, J., Chiba, Y., & Yamazaki, H. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.11.011 · Cited by 18
Genotype‐sensitive reversible and time‐dependent CYP 2D6 inhibition in human liver microsomes
Storelli, F., Desmeules, J. A., & Daali, Y. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13124 · Cited by 16 · cited 1×
“In a follow-up in-vitro study using human liver microsomes, the authors showed that the phenoconversion is likely to be explained through a difference in the amount of functional CYP2D6 enzyme and not by differences in the potency of the CYP2D6 inhibitors for the different genotypes [49].”
BackgroundGöktaş, M. T., Hatta, F. H. M., Karaca, R. Ö., Kalkışım, S., Kılıç, L., Akdoğan, A., Babaoglu, M. O., Bozkurt, A., Helldén, A., Bertilsson, L., et al. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1899-7 · Cited by 15
Titze, M. I., Schaaf, O., Hofmann, M. H., Sanderson, M. P., Zahn, S. K., Quant, J., & Lehr, T. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3049-z · Cited by 5
Cited by
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
“, inhibitors, inducers), diet, smoking, age, disease conditions, and inflammatory status [29].”
Metadata
- Authors
- Klomp, S. D., Manson, M. L., Guchelaar, H.-J., & Swen, J. J.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-09-07
- Volume
- 9
- Issue
- 9
- Pages
- 2890
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3083299599
- Cited by
- 185
- References
- 63
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.